Physician profile
Julia Cunningham
NPI 1487949335
$808.19
in general payments reported to CMS, 2019-2025
18 companies · $212 in 2025
The $212 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $14.83 · 2021: $150 · 2022: $47.38 · 2024: $89.82 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $287 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $287.27 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $315.00 | 2019-2024 | Ultomiris |
| Bioverativ Therapeutics INC. | $120.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $90.34 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $74.82 | 2024 | Xpovio |
| Janssen Biotech, INC. | $39.83 | 2025 | Erleada, Talvey, Tecvayli |
| Merck Sharp & Dohme LLC | $27.13 | 2025 | Keytruda |
| Celgene Corporation | $24.86 | 2022 | |
| Genentech USA, INC. | $23.76 | 2025 | Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $22.52 | 2022 | |
| Incyte Corporation | $21.38 | 2025 | Zynyz |
| Accord Healthcare, INC. | $18.81 | 2025 | |
| Puma Biotechnology, INC. | $14.98 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $14.76 | 2025 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.